Sunil Pancholi
YOU?
Author Swipe
View article: Correction: Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer
Correction: Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer Open
View article: Figure 3 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Figure 3 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
CDK9 inhibitors impair cell viability in 2D and 3D culture. A and B, A total of 4,000 to 8,000 cells were seeded in 96-well tissue culture plates and treated at day 1 and 3 with the CDK9 inhibitors NVP-2 (A) or AZD4573…
View article: Supplementary Figure S1 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S1 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S1
View article: Data from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Data from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
The combination of endocrine therapy and CDK4/6 inhibitors such as palbociclib is an effective and well-tolerated treatment for estrogen receptor–positive (ER+) breast cancer, yet many patients relapse with therapy-resistant dis…
View article: Supplementary Data from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Data from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Methods
View article: Supplementary Figure S4 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S4 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S4
View article: Supplementary Figure S2 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S2 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S2
View article: Figure 1 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Figure 1 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Two-dimensional kinase inhibitor screens in LTED breast cancer cell line models. A, Schematic representation of the study. B, 2D screens at 1 μmol/L final drug concentration (see Materials and Methods). Sigma plots represent …
View article: Supplementary Figure S5 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S5 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S5
View article: Supplementary Figure S4 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S4 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S4
View article: Figure 1 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Figure 1 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Two-dimensional kinase inhibitor screens in LTED breast cancer cell line models. A, Schematic representation of the study. B, 2D screens at 1 μmol/L final drug concentration (see Materials and Methods). Sigma plots represent …
View article: Figure 3 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Figure 3 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
CDK9 inhibitors impair cell viability in 2D and 3D culture. A and B, A total of 4,000 to 8,000 cells were seeded in 96-well tissue culture plates and treated at day 1 and 3 with the CDK9 inhibitors NVP-2 (A) or AZD4573…
View article: Figure 4 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Figure 4 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
CDK9 inhibitor AZD4573 drives tumor regression in endocrine therapy and palbociclib-resistant PDXs. A, 2–5 × 104 dissociated PDO cells were seeded per well in 96-well tissue culture plates in 10% Matrigel. The resulting o…
View article: Supplementary Tables from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Tables from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Tables S1, S2, S3, S4, S5a, S5b, S5c, S5d, S6
View article: Supplementary Figure S1 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S1 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S1
View article: Supplementary Tables from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Tables from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Tables S1, S2, S3, S4, S5a, S5b, S5c, S5d, S6
View article: Figure 4 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Figure 4 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
CDK9 inhibitor AZD4573 drives tumor regression in endocrine therapy and palbociclib-resistant PDXs. A, 2–5 × 104 dissociated PDO cells were seeded per well in 96-well tissue culture plates in 10% Matrigel. The resulting o…
View article: Figure 2 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Figure 2 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Three-dimensional kinase inhibitor screens in LTED and palbociclib-resistant breast cancer cell line models. Three-dimensional assays were performed at 250 nmol/L final drug concentration (see Materials and Methods). Compounds with a robus…
View article: Figure 2 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Figure 2 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Three-dimensional kinase inhibitor screens in LTED and palbociclib-resistant breast cancer cell line models. Three-dimensional assays were performed at 250 nmol/L final drug concentration (see Materials and Methods). Compounds with a robus…
View article: Supplementary Figure S2 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S2 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S2
View article: Supplementary Figure S3 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S3 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S3
View article: Data from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Data from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
The combination of endocrine therapy and CDK4/6 inhibitors such as palbociclib is an effective and well-tolerated treatment for estrogen receptor–positive (ER+) breast cancer, yet many patients relapse with therapy-resistant dis…
View article: Supplementary Figure S5 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S5 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S5
View article: Supplementary Data from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Data from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Methods
View article: Supplementary Figure S3 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers
Supplementary Figure S3 from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER<sup>+</sup> Breast Cancers Open
Supplementary Figure S3
View article: Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers Open
The combination of endocrine therapy and CDK4/6 inhibitors such as palbociclib is an effective and well-tolerated treatment for estrogen receptor–positive (ER+) breast cancer, yet many patients relapse with therapy-resistant disease. Deter…
View article: Figures S1-S6 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Figures S1-S6 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
ESR1 mutants are resistant to endocrine therapies in vitro and in vivo and H3B-5942 can suppress ER pathway activity.
View article: S5. Validation of target genes within pathways shown to be up-regulated by AZD5363 treatment. from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) <i>In Vivo</i>
S5. Validation of target genes within pathways shown to be up-regulated by AZD5363 treatment. from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) <i>In Vivo</i> Open
MCF7 and MCF7-LTED cells lines were cultured in DCC {plus minus} AZD5363 and mRNA analysis performed by RT-qPCR. Error bars represent {plus minus} SEM. *p<0.05; **p<0.01; ***p<0.001. Coloured dots indicate which signalling pathways each ge…
View article: Data from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) <i>In Vivo</i>
Data from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) <i>In Vivo</i> Open
PI3K/AKT/mTOR signaling plays an important role in breast cancer. Its interaction with estrogen receptor (ER) signaling becomes more complex and interdependent with acquired endocrine resistance. Targeting mTOR combined with endocrine ther…
View article: Supplementary Methods from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Supplementary Methods from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
Additional methods provided.